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Purpose: The objective of this pilot trial was to evaluate the safety and efficacy of AKL1, 
a patented botanical formulation containing extracts of Picrorhiza kurroa, Ginkgo biloba, and 
Zingiber officinale, as add-on therapy for patients with chronic obstructive pulmonary disease 
(COPD) and chronic cough.
Patients and methods: This randomized, double-blind, placebo-controlled trial enrolled male 
and female patients .18 years old with COPD and Leicester Cough Questionnaire (LCQ) score 
of ,18. The 10-week study period comprised a 2-week single-blind placebo run-in period fol-
lowed by add-on treatment with AKL1 or placebo twice daily for 8 weeks. The primary study 
endpoint was the change from week 0 to week 8 in cough-related health status, as assessed by 
the LCQ.
Results: Of 33 patients enrolled, 20 were randomized to AKL1 and 13 to placebo. Patients 
included 19 (58%) men and 14 (42%) women of mean (standard deviation [SD]) age of 67 (9.4) 
years; 15 (45%) patients were smokers and 16 (49%) were ex-smokers. The mean (SD) change 
from baseline in LCQ score at 8 weeks was 2.3 (4.9) in the AKL1 group and 0.6 (3.7) in the 
placebo group, with mean difference in change of 1.8 (95% confidence interval: −1.5 to 5.1; 
P=0.28). The St George’s Respiratory Questionnaire score improved substantially in the AKL1 
treatment group by a mean (SD) of −7.7 (11.7) versus worsening in the placebo group (+1.5 [9.3]), 
with mean difference in change of −9.2 (95% confidence interval: −19.0 to 0.6; P=0.064). There 
were no significant differences between treatment groups in change from baseline to week 8 in 
other patient-reported measures, lung function, or the 6-minute walk distance.
Conclusion: Further study is needed with a larger patient population and over a longer duration 
to better assess the effects of add-on therapy with AKL1 in COPD.
Keywords: Leicester Cough Questionnaire, anti-inflammatory, Picrorhiza kurroa, Ginkgo 
biloba, Zingiber officinale
Introduction
The goal of pharmacologic therapy for chronic obstructive pulmonary disease (COPD) 
is to control symptoms, reduce exacerbation frequency, and improve quality of life; 
however, the results of standard pharmacologic therapy are often unsatisfactory, mani-
festing as restricted activity and impaired quality of life, as well as exacerbations and 
hospitalizations.1 Patients often show poor adherence to and persistence with COPD 
regimens;2–4 their concerns about chronic therapy for COPD frequently center around 
lack of confidence in the efficacy and safety of medications.4,5
Inhaled bronchodilators are currently the mainstay of COPD therapy. The need 
for concomitant anti-inflammatory therapy is well recognized; however, the  majority 
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of patients with COPD show corticosteroid resistance, and 
the optimal means of treating the underlying airway inflam-
mation in COPD remains under active investigation.6–9 
Patients with COPD often use complementary and alterna-
tive medicines.4,10 Herbal medicines have been used for 
centuries in the People’s Republic of China and other parts 
of Asia for treating respiratory diseases, and many natural 
agents have anti-inflammatory effects.7,11,12
A new patented formulation, AKL1 (AKL International, 
Ltd, Guernsey, UK), comprising standardized extracts of 
Picrorhiza  kurroa, Ginkgo biloba, and Zingiber officinale, 
has been developed as adjunctive therapy for patients with 
obstructive lung disease (COPD and asthma). The active 
compounds picroliv, androsin, and apocynin contained in 
P. kurroa, an herb used in Ayurvedic medicine to treat liver 
and lung diseases, have demonstrated anti- inflammatory 
activities. In vitro, picroliv inhibits the nuclear factor-
kappaB activation pathway,13 while in guinea pigs, androsin 
prevents bronchial obstruction induced by allergen and 
platelet-activating factor.14 Apocynin abrogates the agonist-
induced contraction of airway smooth muscle from patients 
with asthma by blocking the activation of nicotinamide 
adenine dinucleotide phosphate oxidase; in patients with 
mild asthma, nebulized apocynin reduces the concentration 
of reactive oxygen and reactive nitrogen species in exhaled 
breath condensate.15,16 Extracts of G. biloba ameliorate 
eosinophilic inflammation in lung epithelia and suppress 
nuclear factor-kappaB activation,17,18 as well as reduce 
levels of interleukin-5 and inflammatory cells containing 
protein kinase C (eosinophils and lymphocytes) in induced 
sputum when given in addition to inhaled corticosteroids 
to patients with asthma.19
The AKL1 formulation, not yet available commercially, 
is manufactured using strict standardization of its individual 
botanical components against specific proprietary phy-
tochemical markers to ensure batch-to-batch consistency, 
as previously described.20 The results of a small pilot study20 
suggest that AKL1 may be efficacious as adjunctive therapy 
for patients with asthma to improve symptoms and quality 
of life. Patient-centered outcomes, including the Leices-
ter Cough Questionnaire (LCQ) scores, showed trends to 
improvement with AKL1 relative to placebo.20 Our objective 
in this trial was to evaluate the safety and efficacy of AKL1 
as add-on therapy for patients with COPD who had chronic 
cough despite their current management. Our hypothesis 
was that AKL1 would improve cough-related quality of life 
as assessed using the LCQ.
Methods
Trial design
This randomized, double-blind, placebo-controlled, parallel-
group trial was conducted from June 2009 through  February 
2011 at a single site at the University of East Anglia,  Norwich, 
UK. The 10-week study period comprised a 2-week single-
blind placebo run-in period (to identify nonadherent patients 
and minimize the placebo effect during the study) followed by 
an 8-week treatment period. Four study visits were scheduled: 
1) at the start of the run-in period (week −2); 2) at baseline 
(week 0); 3) after 4 weeks’ treatment (week 4); and 4) at study 
end (week 8). The study duration of 8 weeks was chosen 
because we expected to find clinically relevant improvements 
during this time period, based on results of an earlier pilot 
study (Smith et al, unpublished data, 2012). 
During the 2-week screening period from visit 1 to visit 
2, all patients received single-blind placebo in addition to 
their usual treatment. Patients who remained eligible for the 
study at baseline (week 0) were randomly assigned in a 1:1 
ratio, using a block randomization procedure with block size 
of four (not known to investigators), to receive oral AKL1 or 
placebo in addition to their current medication. Randomized 
treatment consisted of AKL1 or identical placebo (containing 
calcium phosphate and magnesium stearate) taken as two 
capsules twice daily at the same time each morning (7 am 
to 10 am) and each evening (7 pm to 10 pm). The AKL1 
administered in this study was produced according to UK 
Good Manufacturing Practices.21
Patients
Patients eligible for the study were male and female adults 
(.18 years old) who had a diagnosis of obstructive lung 
disease and nonreversible airflow limitation, as defined by 
a postbronchodilator ratio of forced expiratory volume in 
1 second (FEV
1
) to forced vital capacity of ,0.722 at visit 2. 
In addition, at visit 1 or 2, all eligible patients had a post-
bronchodilator FEV
1
 of ,80% and evidence of persistent 
symptoms as 1) an LCQ score of ,18; and 2) a modified 
Medical Research Council (MRC) dyspnea score of $3 or 
a modified MRC dyspnea score of $2 plus Clinical COPD 
Questionnaire (CCQ) score $1.5.
Enrolled patients were required to be in satisfactory 
health other than obstructive lung disease, as determined 
by investigators on the basis of medical history and physi-
cal  examination. In addition, during the screening period, 
eligible patients had to demonstrate satisfactory ability to 
use a salbutamol metered-dose inhaler. Female patients had 
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to be .1 year postmenopausal, surgically sterilized, or, if 
of childbearing potential, using adequate contraception, 
not breastfeeding, and testing negative for pregnancy on a 
urine test.
Smokers were not excluded from the study. Key exclu-
sion criteria were maintenance oral corticosteroids, seasonal 
disease, or an exacerbation or recent change in maintenance 
therapy within 6 weeks before visit 1. Patients unable to 
discontinue short-acting β-agonists for at least 4 hours, 
long-acting β-agonists for 12 hours, or tiotropium for 
48 hours before visit 2 (baseline) were also excluded. Any 
other severe acute or chronic medical or psychiatric condi-
tion that, in the judgment of the investigator, would make 
the patient inappropriate for entry into the study was cause 
for exclusion.
Antibiotics were not permitted within 6 weeks before 
the study. Medications not allowed for 3 months before and 
during the study included oral anticoagulants, antiepileptic 
medication, long-term systemic corticosteroids, long-term 
oxygen therapy (to exclude the most severe patients), and 
other investigational drugs. Other treatments prescribed for 
concomitant diseases not interfering with the study evalu-
ations were allowed during the trial period, providing their 
use did not change during the study. Oral corticosteroids for 
2 weeks and antibiotics could be prescribed during the study 
as medically necessary.
The study was conducted in accordance with Good 
Clinical Practice including Research Ethics Committee 
(08/H0305/54) and Medicines and Healthcare products 
Regulatory Agency (2222-222222-22) approval, and all par-
ticipating patients gave written informed consent. The study 
was registered on the ClinicalTrials.gov website.23
Procedures and study outcome measures
The primary study endpoint was the change from week 0 
to week 8 in cough-related health status, as assessed by the 
LCQ.24 The LCQ is a self-administered instrument compris-
ing 19 items, each scored on a 7-point Likert-type scale from 
1 (worst status) to 7 (best status) and averaged within three 
domains (physical, psychological, and social). The three 
domain scores are then totaled for a final score ranging from 
3 to 21, with higher score indicating a better health-related 
quality of life.24 The minimal clinically important difference 
(MCID) for the LCQ is 1.3.25
Secondary endpoints included the COPD-specific health 
status using the St George’s Respiratory Questionnaire 
(SGRQ), on which scores range from 0 to 100, with lower 
scores indicating improvement and an MCID of 4 units;26,27 
the CCQ score, which ranges from 0 (best) to 6 (extremely 
symptomatic/total limitation) with MCID of 0.4;28–31 and 
the modified MRC dyspnea score, scored from 1 (breathless 
only with strenuous exercise) to 5 (too breathless to leave 
the house or breathless when dressing or undressing).32–34 In 
addition, we assessed exercise impairment as measured by 
the 6-minute walk distance test.35,36
At visit 1, after informed consent was obtained, 
a complete medical history was taken, a physical examina-
tion was performed, clinical laboratory tests were drawn, 
and patients were assessed for trial eligibility. Screening 
respiratory testing included spirometry, the 6-minute walk 
test, and administration of the LCQ, SGRQ, and modified 
MRC questionnaires. Spirometry was performed according 
to American Thoracic Society and European Respiratory 
Society guidelines.37,38
Testing at week 0 and week 8 included spirometry, the 
6-minute walk test, and four questionnaires (LCQ, SGRQ, 
CCQ, and modified MRC). Testing at visit 3, after 4 weeks 
on AKL1 or placebo, included spirometry and the LCQ and 
SGRQ.
Salbutamol metered-dose inhalers were provided as 
 rescue medication at visit 1 and throughout the study period 
as needed. Adverse events were monitored at each study 
visit, and liver and kidney function were assessed at the first 
and last visit.
statistical analysis
The primary efficacy endpoint was the change in LCQ score 
between week 0 and week 8. Sample size calculations were 
based on pilot study results20 and assuming a clinically impor-
tant change in the LCQ of 0.5, with standard deviation (SD) 
of 1.04 for the change. We calculated that to achieve 80% 
power at a significance level of 5%, 69 evaluable patients 
in each arm were required, for a total of 82 patients per 
study arm, allowing for 15% drop-outs. Using the newer 
clinically important difference of 1.3 units,25 a sample size 
of 22 patients would be required.
Summary statistics were used to examine differences in 
baseline and outcome variable distributions between treat-
ment groups. The primary analysis was conducted using 
an intention-to-treat approach, including all randomized 
patients, comparing baseline (visit 2) and outcome (visit 4) 
results using analysis of variance; we used the χ2 test for cat-
egorical variables. A separate analysis using Student’s t-test 
was carried out to test the differences, with 95% confidence 
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Table 1 Baseline demographic and clinical characteristics of 
enrolled patients
AKL1 (N=20) Placebo (N=13)
n Mean (SD)  
or n (%)
n Mean (SD) 
or n (%)
age (years) 20 66.9 (11.1) 13 67.3 (6.5)
Male sex n (%) 20 12 (60) 13 7 (54)
Body mass index (kg/m2) 20 27.0 (4.3) 13 30.0 (6.6)
smoking status n (%) 
 Current smoker 
 ex-smoker 
 nonsmoker
20  
10 (50) 
9 (45) 
1 (5)
13  
5 (39) 
7 (54) 
1 (8)
Baseline spirometry, post-bronchodilatora
 FeV1 (l) 18 1.5 (0.7) 12 1.6 (0.6)
 FeV1 (%predicted) 19 57.9 (17.2) 12 57.3 (16.3)
6-minute walk distance (m) 20 294 (181) 13 347 (145)
leicester Cough  
Questionnaire score
19 12.1 (3.0) 13 14.6 (2.5)
sgrQ total score, units 17 62.5 (14.7) 11 54.3 (16.2)
 sgrQ – symptoms domain 75.7 (16.1) 65.0 (17.7)
 sgrQ – activity domain 79.9 (17.1) 68.9 (21.6)
 sgrQ – impact domain 48.8 (16.5) 42.4 (16.1)
Clinical COPD  
Questionnaire score
20 3.3 (1.0) 13 2.9 (1.1)
Modified MRC dyspnea score 20 3.0 (0.6) 12 3.2 (0.4)
Medications at baseline n (%) 
 saBa only 
 ICs only 
 laBa only 
 laMa only 
 ICs + laBa 
 ICs + laBa + laMa 
 Missing
20  
1 (5) 
1 (5) 
1 (5) 
3 (15) 
6 (30) 
6 (30) 
2 (10)
13  
1 (8) 
2 (15) 
0 
2 (15) 
3 (23) 
2 (15) 
3 (23)
Notes: Values expressed as means (sD) unless otherwise noted. aall patients had 
an FeV1/FVC ratio of ,0.7 at visit 2 (baseline).
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; ICs, inhaled corticosteroid; laBa, long-acting β-agonist; laMa, long-
acting muscarinic antagonist; MrC, Medical research Council; saBa, short-acting 
β-agonist; sD, standard deviation; sgrQ, st george’s respiratory Questionnaire.
intervals (CIs), between the two arms in mean change from 
baseline to outcome in key variables.
In addition, because of missing data, we performed an 
exploratory analysis using the last-observation-carried-
 forward (LOCF) approach, allowing visit 1 values for 
baseline and visit 3 for outcome when visit 2 or 4 values, 
respectively, were missing.
Statistically significant results were defined as P,0.05. 
Statistical analyses were conducted using SPSS software 
(v 19; IBM Corporation, Armonk, NY, USA).
Results
Patients
A total of 78 patients were screened for the study at eleven 
sites/practices; of these, 33 (42%) patients were enrolled in 
the study at the University of East Anglia site, and 32 of the 
33 patients attended all four visits (one patient completed 
only the first three visits). Patients ranged in age from 41 to 
80 years (mean [SD] 67 [9.4] years) and included 19 (58%) 
men and 14 (42%) women. Body mass index ranged from 
18 to 39 kg/m2 (mean [SD] 28.1 [5.4] kg/m2). Most patients 
were current smokers (15 [45%]) or ex-smokers (16 [49%]); 
two (6%) patients had never smoked. The majority of patients 
were receiving inhaled corticosteroids and long-acting bron-
chodilators with or without tiotropium therapy.
Patient demographic and baseline clinical characteris-
tics are summarized in Table 1. The two treatment groups 
were similar with regard to mean lung function measures 
(see Table 1), with FEV
1 
%predicted ranging from 20% to 
80% in the AKL1 treatment group and from 20% to 79% 
in the placebo group. Patient-reported measures tended to 
be worse in the AKL1 group, with LCQ score range from 
6.5 to 16.7 at baseline, compared with 10.2 to 19.8 in the 
placebo group. Similarly, the SGRQ, for which a higher 
score is worse, ranged from 36 to 86 in the AKL1 treatment 
group and from 20 to 73 in the placebo group. The means at 
baseline are reported in Table 1.
health-related quality of life:  
patient-reported measures
There was no significant difference between treatment groups 
in the change from baseline in the LCQ score at 8 weeks, 
the primary endpoint (Table 2). Changes in the CCQ and 
the MRC dyspnea scores were also similar for patients who 
received AKL1 or placebo. The SGRQ improved substan-
tially more in the AKL1 treatment group than in the placebo 
group, falling by a mean of 7.7 points as compared with a 
mean increase of 1.5 points for placebo (P=0.064); however, 
the SGRQ analyses included just 13 of 20 patients and nine 
of 13 patients in the AKL1 and placebo groups, respectively, 
who had data for all visits (Table 2). Each of the three SGRQ 
domain scores showed similar patterns to the SGRQ total 
score, with mean decreases in the AKL1 group and mean 
increases in the placebo group but no significant differences 
between groups (Table 2). In the AKL1 treatment group, 
mean improvements in the LCQ and SGRQ scores, both 
absolute and relative to placebo, were greater than the MCID 
for those measures.
The LOCF analysis was consistent with the main 
 intention-to-treat analysis; there were no significant differ-
ences between treatment groups (data not shown).
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Table 2 Mean change from baseline to outcome, and difference between treatment groups in mean change, in study endpoints after 
8 weeks of treatment with aKl1 or placebo
AKL1 (N=20) Placebo (N=13) Difference in mean  
change (95% CI)
P-valuea
n Mean (SD) n Mean (SD)
spirometry, postbronchodilator
 FeV1 (l) 16 −0.1 (0.2) 11 −0.2 (0.2) 0.09 (−0.07 to 0.25) 0.27
 FeV1 (%predicted) 17 −5.4 (13.5) 12 −5.0 (7.1) −0.4 (−9.2 to 8.4) 0.92
6-minute walk distance (m) 19 −5.5 (61.4) 13 −13 (64.5) 7 (−39 to 54) 0.74
lCQ score 19 2.3 (4.9) 13 0.6 (3.7) 1.8 (−1.5 to 5.1) 0.28
sgrQ total score, units 13 −7.7 (11.7) 9 1.5 (9.3) −9.2 (−19.0 to 0.6) 0.064
 sgrQ – symptoms domain −6.2 (14.6) 2.2 (14.5) −8.5 (−19.3 to 2.4)
 sgrQ – activity domain −10.0 (17.0) 1.6 (10.4) −11.6 (−26.2 to 3.0)
 sgrQ – impact domain −4.9 (11.7) 3.5 (11.5) −8.4 (−18.5 to 1.8)
CCQ score 19 −0.01 (0.6) 13 0.1 (0.7) −0.07 (−0.5 to 0.4) 0.76
Modified MRC dyspnea score 17 −0.2 (0.8) 12 −0.2 (0.6) not applicable 0.23
Notes: The minimal clinically important differences are as follows: 1.3 for the lCQ (higher score is better);24 4.0 for the sgrQ (lower is better);26 and 0.4 for the CCQ 
(lower is better).27 astudent’s t-test for FeV1 and FeV1 %predicted, 6-minute walk distance, CCQ, lCQ, and sgrQ, and χ2 test for the MrC comparing the two treatment 
groups for change from baseline to outcome. aKl1: aKl International, ltd, guernsey, UK.
Abbreviations: CCQ, Clinical COPD Questionnaire; CI, confidence interval; FEV1, forced expiratory volume in 1 sec; lCQ, leicester Cough Questionnaire; MrC, Medical 
research Council; sD, standard deviation; sgrQ, st george’s respiratory Questionnaire.
Objective measures
There were no significant differences between treatment 
groups in change from baseline to week 8 in lung function 
or the 6-minute walk distance (Table 2).
adverse events
No COPD exacerbations were recorded during the study.
Five patients reported adverse events. Chest infections 
were diagnosed in one patient in each treatment allocation 
group: one in the placebo group at baseline (visit 2) and one 
in the AKL1 group at the final visit (visit 4). In the AKL1 
group, one patient reported nightmares and one patient had 
right shoulder pain at the baseline visit, and one patient had 
influenza at the final visit.
Discussion
We found no significant improvement relative to placebo 
in the primary study endpoint of cough-related quality 
of life on the LCQ for patients with COPD who received 
add-on therapy with AKL1 twice daily for 8 weeks in 
this small, randomized, double-blind trial. Moreover, 
no significant differences between AKL1 and placebo 
groups were recorded for other study measures. Of note, 
however, AKL1 treatment resulted in mean improve-
ments in LCQ and SGRQ, both absolute and relative to 
placebo, that were greater than the MCID for each of 
those measures. There were no exacerbations of COPD, 
and no AKL1-related safety concerns were raised during 
the study.
Complementary and alternative medicinal approaches 
have been used for centuries to treat a wide variety of  ailments; 
however, there is a need for well-designed clinical trials to 
evaluate efficacy and safety of potential therapies.39,40 This 
is the first randomized controlled trial to investigate the 
efficacy of AKL1 as add-on therapy for patients with COPD 
and chronic cough. In a prior crossover study, in which 
AKL1 and placebo were each administered for 12 weeks as 
add-on therapy for 32 patients with asthma uncontrolled on 
standard treatment, no significant differences in lung func-
tion or secondary outcomes were recorded; however, trends 
in the patient-reported asthma control measures favored 
AKL1 therapy.20
We chose cough as the primary endpoint for this study, 
in part because the LCQ had shown trends to improvement 
in the previous asthma study;20 moreover, cough is a trouble-
some symptom for patients and responds poorly to existing 
therapies. However, our study, similar to the previous asthma 
study,20 was small and may have been insufficiently powered 
to detect a significant effect of AKL1 therapy. In addition, 
a longer course of treatment may have revealed a statistically 
significant divergence in outcomes for AKL1- and placebo-
treated patients.
A study limitation is that some outcome measures were 
not completed by all patients at all visits. To address this limi-
tation, we conducted the LOCF analysis, whereby we were 
able to include data from almost all patients, thus increasing 
statistical power and reducing risk of bias from selective loss 
of patients. The results of the LOCF analysis, while not per 
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protocol, and therefore exploratory, were consistent with 
those of the per-protocol analysis.
A strength of this study is that we enrolled patients 
from the community who were representative of the patient 
population with COPD seen in general practice, including 
male and female patients, the majority of them smokers or 
ex-smokers. Two patients were nonsmokers and had fixed 
airflow obstruction due to chronic asthma. Their disease is 
likely to be pathophysiologically different from that of the 
smokers, although a comparison was outside the scope of this 
study. We used multiple outcome measures, both objective 
and patient-reported, to assess the effects of therapy on the 
heterogeneous symptoms of COPD.
Conclusion
Results of this small study showed no significant improve-
ment compared with placebo in the primary study endpoint 
of cough-related quality of life, as assessed using the LCQ, 
for patients with COPD receiving AKL1 as add-on therapy. 
However, we note that, in the AKL1 treatment group, the 
mean improvements in the LCQ and SGRQ scores, both 
absolute and relative to placebo, were greater than the MCID 
for those measures. Moreover, the substantial improvement 
in the SGRQ score among AKL1-treated patients suggests 
there may be a beneficial effect of treatment with AKL1. 
Further study is needed with a larger patient population and 
over a longer duration to better assess the effects of add-on 
therapy with AKL1 in COPD.
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